RespireRx Pharmaceuticals Inc (fka RSPI)

[spyderboi]

I cant tell you anything about that compound, but the grapefruit juice exclusion is likely to mean the drug can be metabolised by Cytochrome P-450 3A4 and may have a narrow therapeutic window.
CYP-3A4 is responsible for metabolism of 70% of drugs in the liver, but also occurs in the intestine. It has been found that grapefruit juice can inhibit 3A4 and therefore affect the drug bioavialabilty. This is usually not important, but if a drug only has efficacy close to its toxic level then such variability in its bioavailablity can be very significant.
Im not sure your guess of high potency is necessarily accurate- they are starting at 0.25mg then rising from there. That suggests they just dont know.

My best guess would be- Hi impact since only cortex seems to work on LI And the concern about starting dose and tight controls of bioavailablity suggests a concern with toxicity- probably seizure- again a feature of HI ampakines.

Hope that helps